OpenAlex
Panitumumab Plus Trifluridine-Tipiracil as Anti–Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer
Work
Year: 2023
Type: article
Abstract: Importance Current third-line therapies for patients with metastatic colorectal cancer (MCRC) have limited efficacy. Rechallenge with epidermal growth factor receptor (EGFR) inhibitors for RAS wild-ty... more
Cites: 15
Cited by: 29
Related to: 10
FWCI: 7.776
Citation percentile (by year/subfield): 100
Subfield: Oncology
Field: Medicine
Sustainable Development Goal Good health and well-being
Open Access status: hybrid